Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 875 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cervix Carcinoma Clear all
Completed No phase listed Observational Accepts healthy volunteers

CROSSROAD II: Activating Rural Clinics and Women With Disabilities to Improve Cancer Screening

NCT01773980
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer, Colorectal Cancer
Interventions
Clinic Intervention, Patient Intervention
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
1,570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 22, 2015 · Synced Oct 24, 2026, 5:24 AM EDT
Terminated Phase 3 Interventional Results available

Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer

NCT00577317
View directory record Official record
Conditions
Lymphedema, Stage 0 Cervical Cancer, Stage 0 Uterine Corpus Cancer, Stage 0 Vulvar Cancer, Stage I Uterine Corpus Cancer, Stage I Vulvar Cancer, Stage IA Cervical Cancer, Stage IB Cervical Cancer, Stage II Uterine Corpus Cancer, Stage II Vulvar Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Uterine Corpus Cancer, Stage III Vulvar Cancer, Stage IV Uterine Corpus Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Stage IVB Vulvar Cancer
Interventions
Management of Therapy Complications, Quality-of-Life Assessment
Procedure · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 24, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available

Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer

NCT04246489
View directory record Official record
Conditions
Uterine Cervical Neoplasms
Interventions
Bintrafusp alfa
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 24, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available

Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery

NCT00331760
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer
Interventions
cisplatin, intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
151
States / cities
Auburn, California • Cameron Park, California • Carmichael, California + 103 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 24, 2026, 5:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Kukui Ahi Navigator Cancer Screening and Treatment Demonstration Project

NCT00379782
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer
Interventions
Navigation
Other
Lead sponsor
Queen's Medical Center
Other
Eligibility
21 Years and older
Enrollment
628 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Kaunakakai, Hawaii
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 24, 2026, 5:24 AM EDT
Terminated Phase 2 Interventional

Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer

NCT00003624
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Neurotoxicity, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Sarcoma
Interventions
amifostine trihydrate, cisplatin, paclitaxel
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
8
States / cities
Orange, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Oct 24, 2026, 5:24 AM EDT
Completed Phase 1Phase 2 Interventional

Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer

NCT00003379
View directory record Official record
Conditions
Cervical Cancer
Interventions
cisplatin, paclitaxel, brachytherapy, radiation therapy
Drug · Radiation
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
31
States / cities
Phoenix, Arizona • Newark, Delaware • Chicago, Illinois + 26 more
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 24, 2026, 5:24 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Self-Collection for Cervical Cancer Screening and HPV Vaccination for Cancer Prevention Among Women in Emergency Care in Northeast Florida

NCT06607874
View directory record Official record
Conditions
Human Papillomavirus-Related Cervical Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 24, 2026, 5:24 AM EDT
Completed Not applicable Interventional

HPV Self-test to Increase Cervical Cancer Screening in Asian Women

NCT04612660
View directory record Official record
Conditions
Cervical Cancer
Interventions
Education on cervical cancer prevetnion, Dynamic group interaction, Physician engagement, Patient Navigation, General Health Education
Behavioral
Lead sponsor
Temple University
Other
Eligibility
30 Years to 55 Years · Female only
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2022 · Synced Oct 24, 2026, 5:24 AM EDT
Completed Phase 1 Interventional

HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA

NCT02379520
View directory record Official record
Conditions
Human Papillomavirus-Related Carcinoma, Human Papillomavirus Positive Oropharyngeal Carcinoma, Human Papillomavirus Positive Cervical Carcinoma, Human Papillomavirus Positive Anal Carcinoma, Human Papillomavirus Positive Vulvar Carcinoma, Human Papillomavirus Positive Penile Carcinoma
Interventions
HPV Specific T Cells, Cytoxan, Fludarabine, Nivolumab
Genetic · Drug · Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 24, 2026, 5:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Cancer Disparities for American Indians in the Rural Intermountain West

NCT00380055
View directory record Official record
Conditions
Prostate Cancer, Colorectal Cancer, Breast Cancer, Cervical Cancer, Lung Cancer
Interventions
Navigation Services, Cancer education
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
Not listed
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
2
States / cities
Great Falls, Montana • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 21, 2011 · Synced Oct 24, 2026, 5:24 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer

NCT02291055
View directory record Official record
Conditions
Cervical Cancer, Cancer, Head and Neck Cancer
Interventions
ADXS11-001, MEDI4736
Drug
Lead sponsor
Advaxis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
17
States / cities
Los Angeles, California • New Haven, Connecticut • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Oct 24, 2026, 5:24 AM EDT
Completed Phase 1 Interventional

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

NCT02835833
View directory record Official record
Conditions
Renal Cell Carcinoma, Colorectal Adenocarcinoma, Non-squamous Non-small Cell Lung Cancer, Platinum-refractory Ovarian Carcinoma, Cervical Carcinoma
Interventions
Nintedanib, Bevacizumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 24, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available

A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer

NCT04300647
View directory record Official record
Conditions
Cervical Cancer
Interventions
Tiragolumab, Atezolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Phoenix, Arizona • Irvine, California • Augusta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 24, 2026, 5:24 AM EDT
Completed Not applicable Interventional

Facilitating Follow-Up Adherence for Abnormal Pap Smears

NCT01561326
View directory record Official record
Conditions
Uterine Cervical Neoplasms
Interventions
Cognitive-affective barriers counseling, Cognitive-affective barriers counseling via brochure, standard care
Behavioral
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Oct 24, 2026, 5:24 AM EDT
Terminated Phase 2 Interventional

Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer

NCT00002478
View directory record Official record
Conditions
Cervical Cancer, Ovarian Cancer
Interventions
etoposide
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
47
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Oct 24, 2026, 5:24 AM EDT
Terminated Phase 1 Interventional

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

NCT04458259
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
PF-07265807, Sasanlimab, Axitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
25
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 24, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available

Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer

NCT00381888
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma, Thromboembolism, Vaginal Cancer, Vulvar Cancer
Interventions
fondaparinux sodium
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Minneapolis, Minnesota • Upland, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 24, 2026, 5:24 AM EDT
Terminated Phase 2 Interventional Results available

Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix

NCT00626561
View directory record Official record
Conditions
Cervical Cancer, Uterine Cancer
Interventions
Bevacizumab, Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2014 · Synced Oct 24, 2026, 5:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Early Versus Traditional Follow-Up on Breastfeeding Rates at 6 Months

NCT02221895
View directory record Official record
Conditions
Pregnancy, Breastfeeding, Contraception, Cervical Cancer, Postpartum Depression
Interventions
Postpartum follow up appointment 2-3 weeks after delivery, Postpartum follow up 6-8wk after delivery
Other
Lead sponsor
Madigan Army Medical Center
Federal
Eligibility
18 Years to 50 Years · Female only
Enrollment
344 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Oct 24, 2026, 5:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

NCT03241173
View directory record Official record
Conditions
Advanced Malignancies
Interventions
INCAGN01949, Nivolumab, Ipilimumab
Drug
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
15
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 24, 2026, 5:24 AM EDT
Active, not recruiting Not applicable Interventional

Yoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Being in Patients With Stage IB2-IIIB Cervical Cancer

NCT04622670
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB2 Cervical Cancer FIGO 2018, Stage IB3 Cervical Cancer FIGO 2018, Stage II Cervical Cancer FIGO 2018, Stage IIA Cervical Cancer FIGO 2018, Stage IIA1 Cervical Cancer FIGO 2018, Stage IIA2 Cervical Cancer FIGO 2018, Stage IIB Cervical Cancer FIGO 2018, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018
Interventions
Media Intervention, Quality-of-Life Assessment, Questionnaire Administration, Survey Administration, Yoga
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 24, 2026, 5:24 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Acceptability of Human Papillomavirus (HPV) Self-sampling Tools for Cervical Cancer Prevention

NCT03613493
View directory record Official record
Conditions
Cervical Cancer
Interventions
HPV self-sampling kit, Culturally-targeted Fear Appeal Message, Fear Appeal Message, Interview
Diagnostic Test · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 24, 2026, 5:24 AM EDT
Completed Phase 1 Interventional

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

NCT03652077
View directory record Official record
Conditions
Cervical Cancer, Gastric Cancer, Stomach Cancer, Gastroesophageal Junction Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Melanoma, Uveal Melanoma, Merkel Cell Carcinoma, Mesothelioma, MSI, Non-small Cell Lung Cancer, NSCLC, Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck, Small Cell Lung Cancer, Renal Cell Carcinoma, RCC, Triple-negative Breast Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency
Interventions
INCAGN02390
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Jackson, Mississippi • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Oct 24, 2026, 5:24 AM EDT